INSERM is a public institution with a scientific and technical vocation, under the dual auspices of the French Ministry of Health and the Ministry of Higher Education and Research. Its researchers are committed to studying all human diseases, whether common or rare, through their research in the fields of biology, medicine, and public health.
INSERM will be represented in the Fibro-Targets consortium by 2 research groups which are the U1116 associated to the Centre d’Investigation Clinique (CIC) Pierre Drouin, the U1138 - Centre de Recherche les Cordelliers.
Founded in 2000, Inserm-Transfert SA is the private subsidiary of the French Institute for Health and Medical Research (INSERM), dedicated to Technology Transfer and management of European and International collaborative research projects. The company possesses extensive expertise in two core areas: i) Intellectual Property management, Technology Transfer and exploitation of research results; ii) specific tools and gold standard methods for supporting scientists in their international project preparation and management (ex: 24 FP6 and 10 FP7 EC-funded projects are currently managed by the company). Inserm-Transfert SA has a strong expertise in the financial rules and all related contractual aspects of the FP7 program and has already established management links with almost all research organizations in Europe.
The Foundation for Applied Medical Research (FIMA) in collaboration with the University of Navarra and the UTE created a research centre in health sciences, the Centro de Investigación Médica Aplicada (CIMA). FIMA has extended experience in managing research projects, offering a professional environment with widely available support in the area of project management and financial affairs.
The participating unit from within UCD is the Heart Failure Unit (HFU) at St Vincent's University Hospital, a teaching hospital associated with the university. The HFU is a unit dedicated to delivery of care to patients with or at risk for heart failure. The unit has an established record in translational research in methods of heart failure care delivery, BMs in heart failure and prevention of heart failure focusing on identification of risk characteristics highlighting susceptibility. The HFU has a clinical unit providing care for 4,000 patient with or at-risk for heart failure. In association, the unit is linked with a Biomedical Research unit at UCD where BM and other related research is performed
CARIM is a specialised multi-disciplinary research institute of Maastricht University. It is an internationally recognized centre of expertise for cardiovascular research and training, with 65 staff members, 35 post-docs, 86 PhD students and 80 technicians. CARIM's research program focuses on 3 main themes: 1) cardiac function and adaptation (with a focus on molecular mechanisms of heart failure, 2) vascular biology and 3) thrombosis and haemostasis,. CARIM offers an excellent and well-organized multidisciplinary research environment for the development of innovative techniques and studies on diastolic and systolic heart failure and its co-morbidities within the Research Group of Cardiology.
The Hannover Medical School (MHH), founded in 1965, is one of the world's leading university medical centres. Due to its interdisciplinary research MHH has strong collaborative links with many academic and industrial research organizations worldwide. MHH concentrates its research activities to unravel basic mechanisms which will be, in close collaboration with clinical facilities, translated into clinical research. Building on a broad expertise in medicine, immunology, biochemistry, structural biology, genetics, cell biology and infectiology, MHH scientists study human diseases and develop innovative strategies for diagnosis, prevention and therapy. The main research activities focus on transplantation and stem cell research, cardiovascular biology, immunology as well as biomedical technology and implants.
The Medical University of Vienna is the central federal institution responsible for health care and disease control and prevention in Austria, and the central federal reference institution for both applied and response-orientated research as well as for the Public Health Sector. Its high quality work in all field of cardiology includes a broad spectrum of diagnostic and invasive and non-invasive therapies, as well as high throughput clinical, pre-clinical and basic research. The in-house service for researchers includes core facilities for cytometry, genomics, proteomics, all aspects of medical imaging, instrumental analysis of peptides, biobanks and medical physics and biomedical engineering.
Greenpharma is a CRO in the study of natural products for drug discovery with more than 10 years of experience. It provides compound libraries and services in analytical, medicinal and computational chemistry. It uses cutting-edge chemoinformatics tools to accelerate hit finding and lead optimisation coupled with the wealth of the natural molecules chemistry. It participated in FP6 and FP7 EU projects in heart failure and in identifying new antibiotics.
Firalis is a biotech specialized in the development of innovative biomarkers with a particular focus on cardiovascular biomarkers. Core activities of the company include the development of biomarker assays for emerging biomarker as well as clinical qualification of innovative marker for particular indication such as post-AMI prognosis or vasculitides through intensive collaboration with a network of clinical centers. Firalis is recognized by the pharmaceutical industry for its central role in various collaborative projects.
Innoprot is a biotechnology company with extensive R&D component, located in Spain, spin-off from the University of the Basque Country. Innoprot is a provider of in vitro systems for drug discovery & development. INNO staff includes 13 people. One of key skills of INNO scientific staff is their expertise in developing new cell based assays using freshly isolated human and animal primary cells. In these assays, we combine molecular and cell biology technologies and image analysis at cellular and sub-cellular levels, to obtain multiparametric data in order to speeding up the drug discovery. Regarding the "in house" services provided, Inn INNO offers tailored cell line development (fluorescent, stable or knockdown cell lines), DNA cloning service, protein expression, HCS toxicity assays. INNO has developed several cellular disease models, an expertise that will be an added value in the present project. INNO has a broad expertise in multiplex HCS screening technology applied to efficacy assays. These studies allow classifying new chemical entities according to their efficacy degree.
Navarrabiomed-Miguel Servet Foundation is a non-profit, public research centre in Navarra Region in Spain. It was created and originally named "Navarra Biomedical Research Centre" (CIB) in 1997, to provide technical assistance to the scientific community within Navarra Public Health Service. In October 2012, CIB is integrated into the structure of the Miguel Servet Foundation with a brand new name "Navarrabiomed" and would maintain its full functionality.